Clinical Trials Logo

Radiation Retinopathy clinical trials

View clinical trials related to Radiation Retinopathy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04120636 Active, not recruiting - Epiretinal Membrane Clinical Trials

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: March 5, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

NCT ID: NCT04120311 Active, not recruiting - Macular Edema Clinical Trials

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Start date: September 1, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

NCT ID: NCT03085784 Active, not recruiting - Clinical trials for Radiation Retinopathy

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

ARRT
Start date: July 5, 2017
Phase: Phase 2
Study type: Interventional

The ARRT trial will assess the safety and efficacy of 2mg aflibercept for the treatment of radiation retinopathy, including maculopathy and optic neuropathy over 52 weeks.

NCT ID: NCT00540930 Active, not recruiting - Uveal Melanoma Clinical Trials

Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Start date: April 2007
Phase: Phase 4
Study type: Interventional

Uveal Melanoma is the most common primary intraocular malignancy in adulthood. Eye preserving treatments can deliver equivalent life prognosis in the management of small and medium sized uveal melanomas, as compared to enucleation. Plaque radiotherapy has emerged as the most common eye-preserving treatment in the current management of uveal melanoma, but is complicated by visual loss in approximately 70% of patients at 10 years follow-up. Strategies for the prevention and early treatment of radiation retinopathy/maculopathy need to be developed to improve visual outcomes following plaque treatment. Ranibizumab (Lucentis) is the antigen binding fragment of a recombinant, humanized monoclonal antibody, which inhibits the activity of vascular endothelial growth factor A, a mediator in the development of choroidal neovascularization. Lucentis is commonly used in the eye for eye conditions such as age related macular degeneration. This study will investigate the possible benefit of Anti-VEGF therapy (Lucentis) in reducing the incidence of radiation complications following plaque radiation for uveal melanoma.